New Drug Stops Prostate Cancer Spread to Bones

Researchers at the VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have identified a targeted small molecule inhibitor that prevents prostate tumors from spreading to the bones, a stage of the disease that is typically considered incurable.

The drug, known as IVMT-Rx-4, was found to effectively block the function of MDA-9/Syntenin. According to findings published on April 2, 2026, in the journal Pharmacological Research, the inhibitor not only halts the spread of the cancer but also enhances the effectiveness of standard-of-care chemotherapy treatments.

Addressing Bone Metastasis

Prostate cancer is the most frequently diagnosed cancer in men in the United States, excluding skin cancer. While early detection and existing treatment options prevent most men from dying of the disease, the situation changes significantly once the cancer metastasizes to the bone.

Bone metastasis occurs through a complex process where cancer cells embed themselves within bone tissue. Once established, these cells form functional and physical relationships with the surrounding connective tissue, which promotes further tumor growth and compromises the structural integrity of the bones.

Once the cancer reaches this advanced stage, curative options are largely unavailable. This progression often leads to severe skeletal problems, a diminished quality of life, and death.

The Role of IVMT-Rx-4

The study co-led by Paul B. Fisher, the director of VIMM and the Thelma Newmeyer Corman Endowed Chair in Cancer Research at Massey, highlights the urgent need for therapies targeting this specific stage of progression.

Developing effective therapies for prostate cancer bone metastasis—a final stage of prostate cancer progression without any effective treatments—is a medical priority

Paul B. Fisher, MPH, Ph.D., FNAI

By targeting the MDA-9/Syntenin pathway, IVMT-Rx-4 disrupts the mechanisms that allow prostate cancer to migrate to and survive in bone tissue. The research suggests that this targeted approach could represent a paradigm shift in how metastatic tumors are treated, particularly when used in conjunction with existing chemotherapy regimens.

Clinical Context and Implications

The ability to block metastasis to the bone is critical because of the systemic impact of skeletal involvement. The research published in Pharmacological Research indicates that IVMT-Rx-4 addresses one of the most difficult-to-treat phases of the disease.

While the discovery of IVMT-Rx-4 offers a new potential pathway for treatment, it joins a broader landscape of research into metastatic prostate cancer. Other research has explored different targets, such as the TRPV6/CXCR4 complexes to prevent metastasis in castration-resistant prostate cancer, and the use of combinations like enzalutamide with androgen deprivation therapy to extend survival for men with high-volume metastatic hormone-sensitive prostate cancer.

The findings regarding IVMT-Rx-4 provide a new targeted tool that may eventually help patients avoid the incurable stage of bone metastasis or improve the outcomes for those already facing the disease’s advanced stages.